Added to YB: 2026-01-12
Pitch date: 2026-01-02
NVO [bullish]
Novo Nordisk A/S
-10.9%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 322.56
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.27
P/E
10.92
EV/Sales
4.43
Sector
Pharmaceuticals
Category
growth
Show full summary:
50 Stocks for the New Year Pt 3 - Novo Nordisk A/S
NVO: Weight-loss drug distributor (Ozempic, Wegovy) with 5% YOY revenue growth, 13x P/E, 72% ROE. Tailwinds from aging Americans & processed food consumption driving obesity demand. Headwinds include Eli Lilly competition & patent expiries in some countries.
Read full article (1 min)